CytomX announced a $5 million milestone payment from Regeneron for achieving a preclinical goal in their collaboration.
Quiver AI Summary
CytomX Therapeutics announced that it will receive a $5 million preclinical milestone payment as a result of its collaboration with Regeneron, which started in 2022 and was expanded in June 2026. This partnership focuses on developing bispecific antibodies using CytomX’s PROBODY® therapeutic technology and Regeneron's Veloci-Bi® platform, aimed at creating therapies that activate specifically in tumor environments, thereby reducing off-target side effects. CytomX's CEO, Sean McCarthy, highlighted the milestone as an important step in translating scientific advancements into clinical applications. Under the collaboration agreement, Regeneron handles development and commercialization efforts, while CytomX is eligible for up to $4 billion in potential milestone payments and royalties from future product sales. CytomX specializes in conditionally activated therapeutics designed for cancer treatment.
Potential Positives
- CytomX has achieved a significant preclinical milestone, receiving a $5 million milestone payment from Regeneron, indicating progress in their collaborative efforts.
- The collaboration with Regeneron leverages CytomX’s PROBODY® technology, enhancing the potential for innovative treatments that may broaden therapeutic windows and minimize side effects in cancer therapies.
- The partnership has a substantial future financial potential of up to approximately $4 billion through various milestone payments and potential royalties on global net sales.
- Expansion of the collaboration in June 2026 demonstrates strong confidence and alignment between CytomX and Regeneron in advancing new treatment options for cancer patients.
Potential Negatives
- Despite receiving a $5 million milestone payment, the press release highlights the early-stage status of CytomX's product candidates, indicating potential challenges in progressing through clinical trials and achieving further milestones.
- The press release includes extensive forward-looking statements with numerous risks and uncertainties, which may cast doubt on the reliability of future outcomes and the company's ability to meet its objectives.
FAQ
What milestone has CytomX achieved with Regeneron?
CytomX has achieved a preclinical milestone, resulting in a $5 million payment from Regeneron.
When did the CytomX and Regeneron collaboration begin?
The collaboration between CytomX and Regeneron began in 2022 and was expanded in June 2026.
What is the focus of CytomX’s technology?
CytomX focuses on developing conditionally activated PROBODY® therapeutics to improve cancer treatment safety and efficacy.
What potential value does the expanded collaboration with Regeneron hold?
CytomX could receive up to approximately $4 billion in milestone payments and tiered royalties from the collaboration.
What are some key product candidates in CytomX’s pipeline?
Key candidates include varsetatug masetecan (Varseta-M) and CX-801, targeting metastatic colorectal cancer and melanoma, respectively.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CTMX Insider Trading Activity
$CTMX insiders have traded $CTMX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CTMX stock by insiders over the last 6 months:
- CHRISTOPHER OGDEN (Chief Financial Officer) sold 1,624 shares for an estimated $4,953
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CTMX Hedge Fund Activity
We have seen 111 institutional investors add shares of $CTMX stock to their portfolio, and 101 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VENROCK ADVISER, LLC removed 4,982,124 shares (-100.0%) from their portfolio in Q3 2026, for an estimated $13,551,377
- CITADEL ADVISORS LLC added 3,901,206 shares (+125.4%) to their portfolio in Q3 2026, for an estimated $10,611,280
- BANK OF AMERICA CORP /DE/ removed 3,514,747 shares (-23.3%) from their portfolio in Q3 2026, for an estimated $9,560,111
- JEFFERIES FINANCIAL GROUP INC. removed 3,067,864 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $11,504,490
- STATE STREET CORP removed 2,721,381 shares (-23.2%) from their portfolio in Q3 2026, for an estimated $7,402,156
- QUBE RESEARCH & TECHNOLOGIES LTD added 2,363,425 shares (+129.5%) to their portfolio in Q3 2026, for an estimated $6,428,516
- FMR LLC added 1,621,245 shares (+5.0%) to their portfolio in Q3 2026, for an estimated $4,409,786
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$CTMX Analyst Ratings
Wall Street analysts have issued reports on $CTMX in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- JP Morgan issued a "Overweight" rating on 11/12/2026
- Wedbush issued a "Outperform" rating on 11/06/2026
- Guggenheim issued a "Buy" rating on 08/10/2026
To track analyst ratings and price targets for $CTMX, check out Quiver Quantitative's $CTMX forecast page.
$CTMX Price Targets
Multiple analysts have issued price targets for $CTMX recently. We have seen 3 analysts offer price targets for $CTMX in the last 6 months, with a median target of $12.0.
Here are some recent targets:
- Anupam Rama from JP Morgan set a target price of $12.0 on 11/12/2026
- Robert Driscoll from Wedbush set a target price of $12.0 on 11/06/2026
- Michael Schmidt from Guggenheim set a target price of $14.0 on 08/10/2026
Full Release
- CytomX to receive $5 million preclinical milestone payment -
- The CytomX and Regeneron collaboration began in 2022 and was expanded in June 2026 -
EMERYVILLE, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron, triggering a $5 million milestone payment.
The Regeneron and CytomX collaboration agreement combines CytomX’s PROBODY ® therapeutic masking technology with Regeneron’s Veloci-Bi ® bispecific antibody platform to develop bispecifics that remain inactive within systemic circulation until activated by proteases highly enriched in the tumor microenvironment. This approach has the potential to broaden the therapeutic window and minimize off-target side effects for next-generation T-cell engaging therapies.
“Achievement of this first milestone from our Regeneron partnership represents the translation of promising science towards the clinic and underscores the potential synergistic approach of combining our respective technologies. Following the expansion of our collaboration in June 2026, we are excited to advance our aligned vision of bringing highly innovative new treatment options to cancer patients,” said Sean McCarthy, D. Phil, CEO and Chairman of CytomX.
About the Regeneron Collaboration
Under the terms of the Regeneron and CytomX agreement, the companies collaborate on discovery activities to identify and validate conditionally active bispecific antibodies. Regeneron is responsible for funding all preclinical and clinical development and commercialization activities. CytomX is eligible to receive total potential target nomination payments, preclinical, clinical, regulatory and commercial milestones covered under the scope of the expanded collaboration up to approximately $4 billion. CytomX is also eligible to receive tiered royalties on global net sales for any potential products covered under the collaboration.
About CytomX Therapeutics, Inc.
CytomX is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated, masked PROBODY® therapeutics designed to be localized to the tumor microenvironment. By pioneering a novel pipeline of localized biologics, powered by its PROBODY therapeutic platform, CytomX’s vision is to create safer, more effective therapies for the treatment of cancer. CytomX’s robust and differentiated pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates, cytokines and T-cell engagers. CytomX’s clinical-stage pipeline includes varsetatug masetecan (Varseta-M; CX-2051) and CX-801. Varseta-M is a masked, conditionally activated antibody drug conjugate armed with a topoisomerase-1 inhibitor payload and directed toward epithelial cell adhesion molecule (EpCAM). EpCAM is a highly expressed tumor antigen that has previously been undruggable due to expression on normal tissues. Varseta-M is designed to open a therapeutic window for this high potential target and is initially being developed for the treatment of metastatic colorectal cancer. Varseta-M was discovered in collaboration with ImmunoGen, now part of AbbVie. CX-801 is a masked interferon alpha-2b PROBODY® cytokine with broad potential applicability in traditionally immuno-oncology sensitive as well as insensitive (cold) tumors. CX-801 is initially being developed for the treatment of metastatic melanoma. CytomX has established strategic collaborations with multiple leaders in oncology, including Regeneron. For more information about CytomX and how it is working to make conditionally activated treatments the new standard-of-care in the fight against cancer, visit
www.cytomx.com
and follow us on
LinkedIn
and
X
(formerly Twitter)
.
CytomX Therapeutics Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that are difficult to predict, may be beyond CytomX’s control, and may cause the actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied in such statements, including those related to the future potential of partnerships or collaboration agreements and projected cash runway. These forward-looking statements include, but are not limited to, statements relating to the potential benefits, safety and efficacy or progress of CytomX’s or any of its collaborative partners’ product candidates, the potential benefits or applications of CytomX’s PROBODY® therapeutic platform, CytomX’s or its collaborative partners’ ability to develop and advance product candidates into and successfully complete clinical trials and to achieve other preclinical, clinical, regulatory and commercial milestones. Accordingly, you should not place undue reliance on these forward-looking statements. Risks and uncertainties that contribute to the uncertain nature of the forward-looking statements include: the unproven nature of CytomX’s novel PROBODY® therapeutic technology; uncertainties around CytomX’s ability to raise sufficient funds to carry out its planned research and development; the early stage of CytomX’s or its collaborators’ clinical trial product candidates, which are in the initial stages of clinical development, and its or their other product candidates, which are currently in preclinical development, and the process by which preclinical and clinical development could potentially lead to an approved product is long and subject to significant risks and uncertainties, including the possibility that the results of preclinical research and early clinical trials may not be predictive of future results; the risk that interim or preliminary clinical data may change as more patient data become available; the possibility that CytomX’s or its collaborators’ clinical trials will not be successful; the possibility that current preclinical research may not result in additional product candidates; the possibility that CytomX or its collaborators may not be able to realize the full potential of its or their product candidates; possible regulatory developments in the United States and foreign countries, including China and the European Union; and the risk that CytomX or its collaborators may incur higher costs than expected for research and development. Additional applicable risks and uncertainties include those relating to CytomX’s or its collaborator’s preclinical research and development, clinical development, and other risks identified under the heading "Risk Factors" included in CytomX’s Quarterly Report on Form 10-Q filed with the SEC on November 5, 2026 and in CytomX’s subsequent filings with the SEC. The forward-looking statements contained in this press release are based on information currently available to CytomX and speak only as of the date on which they are made. Except as required by applicable law, CytomX does not undertake and specifically disclaims any obligation to update any forward-looking statements, whether as a result of any new information, future events, changed circumstances or otherwise.
PROBODY is a U.S. registered trademark of CytomX Therapeutics, Inc. All other trademarks are the properties of their respective owners.
Company Contact:
Chris Ogden
SVP, Chief Financial Officer
[email protected]
Investor Contact:
LifeSci Advisors
Corey Davis
[email protected]